Study on the Therapeutic Efficacy and Prognosis of Urokinase Combined with Tenecteplase in the Treatment of Acute Cerebral Infarction

急性脑梗死是神经内科最为常见的疾病，该病症不仅导致患者残疾和死亡的风险显著升高，还常伴随多种严重并发症，从而显著损害患者的生存质量与健康状态。同时，这种疾病也给患者家庭和社会医疗保障体系造成了沉重的经济与社会压力。溶栓治疗是被国内外广泛认可的一种行之有效的治疗方法，能够改善缺血性脑组织的血液供应并减轻神经功能缺损。替奈普酶因是目前最新的溶栓药物而备受关注。尤瑞克林同样具有改善局部脑血流量、减少神经细胞凋亡的作用。本文将探讨替奈普酶静脉溶栓治疗后联合尤瑞克林治疗急性脑梗死的可行性及效果。Acute cerebral infarction is the most common disease in neurology, which not only significantly increases the risk of disability and death, but also often accompanied by various serious complications, which significantly damage the patient’s quality of life and health status. At the same time, this disease also causes heavy economic and social pressure on the patient’s family and social medical security system. Thrombolytic therapy is a widely recognized and effective treatment method at home and abroad, which can improve the blood supply of ischemic brain tissue and reduce neurological deficits. Tenecteplase is currently the latest thrombolytic drug and has attracted much attention. Kallidinogenase also has the effect of improving local cerebral blood flow and reducing neuronal apoptosis. This article will explore the feasibility and effectiveness of combining tenecteplase intravenous thrombolysis with urinary kallidinogenase in the treatment of acute cerebral infarction.